PDF herunterladen
Arzneimittelforschung 2009; 59(12): 615-624
DOI: 10.1055/s-0031-1296449
Reviews
Editio Cantor Verlag Aulendorf (Germany)

New Pathogenic and Therapeutic Concepts in Systemic Sclerosis

Thomas Hügle
Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, (United Kingdom)
,
Christiaan A. Huigens
Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, (United Kingdom)
,
Jacob M. van Laar
Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, (United Kingdom)
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
13. Dezember 2011 (online)

    Lizenzen und Reprints

Abstract

Systemic sclerosis (SSc) is an autoimmune disease of unknown origin. The clinical hallmarks are progressive fibrosis of skin and internal organs and vasculo-pathic changes in the form of digital ulcers and pulmonary arterial hypertension. The chronicity and heterogeneity of the disease has hampered research in SSc in the past, but new research tools and animal models have contributed to a greater understanding of the pathogenesis of SSc and resulted in new findings in the fields of genomics, cytokine expression, autoantibodies and abnormalities of blood progenitor or effector cells. As a consequence, targeted therapeutic compounds such as imatinib are currently under clinical investigation. Whilst the search for an effective “targeted therapy” is still ongoing, autologous stem cell transplantation represents a “multi-target” approach aiming at “resetting” the immune system. This review gives an overview of the translation from pathogenic findings into therapeutical application.

Key words

Fibrosis - Pathogenesis - Scleroderma - Stem cell transplantation - Systemic sclerosis - Therapy, cellular, targeted
 

  • References

  • 1 Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am. 2003; May 29 (2) 239-54
    CrossrefPubMedGoogle Scholar
  • 2 Alonso-Ruiz A, Calabozo M, Perez-Ruiz F, Mancebo L. Toxic oil syndrome. A long-term follow-up of a cohort of 332 patients. Medicine. 1993; Sep 72 (5) 285-95
    PubMedGoogle Scholar
  • 3 Magro CM, Crowson AN, Ferri C. Cytomegalovirus-asso-ciated cutaneous vasculopathy and scleroderma sans inclusion body change. Human Pathol. 2007; Jan 38 (1) 42-9
    CrossrefPubMedGoogle Scholar
  • 4 Fonseca C, Lindahl GE, Ponticos M, Sestini P, Renzoni EA, Holmes AM et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med. 2007; Sep 20 357 (12) 1210-1220
    CrossrefPubMedGoogle Scholar
  • 5 Dieude P, Guedj M, Wipff J, Avouac J, Hachulla E, Diot E et al. The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis. Arthritis Rheum. 2008; Jul 58 (7) 2183-8
    CrossrefPubMedGoogle Scholar
  • 6 Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol. 2004; Dec 138 (3) 540-6
    CrossrefPubMedGoogle Scholar
  • 7 Atamas SP, White B. Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev. 2003; Dec 14 (6) 537-50
    CrossrefPubMedGoogle Scholar
  • 8 Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol. 2006; Feb 33 (2) 275-84
    PubMedGoogle Scholar
  • 9 Querfeld C, Eckes B, Huerkamp C, Krieg T, Sollberg S. Expression of TGF-beta 1, -beta 2 and -beta 3 in localized and systemic scleroderma. J Dermatol Sci. 1999; Sep 21 (1) 13-22
    CrossrefPubMedGoogle Scholar
  • 10 Annes JP, Chen Y, Munger JS, Rifkin DB. Integrin alphaV-beta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. J Cell Biol. 2004; Jun 7 165 (5) 723-34
    CrossrefPubMedGoogle Scholar
  • 11 Dziadzio M, Smith RE, Abraham DJ, Black CM, Denton CP. Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology (Oxford). 2005; Dec 44 (12) 1518-24
    CrossrefPubMedGoogle Scholar
  • 12 Carulli MT, Handler C, Coghlan JG, Black CM, Denton CP. Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?. Ann Rheum Dis. 2008; Jan 67 (1) 105-9
    CrossrefPubMedGoogle Scholar
  • 13 Gruschwitz MS, Albrecht M, Vieth G, Haustein UF. In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis. J Rheumatol. 1997; Oct 24 (10) 1936-43
    PubMedGoogle Scholar
  • 14 Bohgaki T, Amasaki Y, Nishimura N, Bohgaki M, Yamashita Y, Nishio M et al. Up regulated expression of tumour necrosis factor {alpha} converting enzyme in peripheral monocytes of patients with early systemic sclerosis. Ann Rheum Dis. 2005; Aug 64 (8) 1165-73
    CrossrefPubMedGoogle Scholar
  • 15 Chizzolini C, Parel Y, De Luca C, Tyndall A, Akesson A, Scheja A et al. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum. 2003; Sep 48 (9) 2593-604
    CrossrefPubMedGoogle Scholar
  • 16 Yamane K, Ihn H, Asano Y, Jinnin M, Tamaki K. Antagonistic effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-beta receptor type II in human dermal fibroblasts. J Immunol. 2003; Oct 1 171 (7) 3855-62
    PubMedGoogle Scholar
  • 17 Hugle T, Gratzl S, Daikeler T, Frey D, Tyndall A, Walker UA. Sclerosing skin disorders in association with multiple sclerosis. Coincidence, underlying autoimmune pathology or interferon induced?. Ann Rheum Dis. 2009; Jan 68 (1) 47-50
    PubMedGoogle Scholar
  • 18 Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H, Newman J et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1999; Feb 42 (2) 299-305
    CrossrefPubMedGoogle Scholar
  • 19 Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum. 2008; May 58 (5) 1465-74
    CrossrefPubMedGoogle Scholar
  • 20 York MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, Lafyatis R. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum. 2007; Mar 56 (3) 1010-20
    CrossrefPubMedGoogle Scholar
  • 21 Kim D, Peck A, Santer D, Patole P, Schwartz SM, Molitor JA et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum. 2008; Jul 58 (7) 2163-73
    CrossrefPubMedGoogle Scholar
  • 22 Kraling BM, Maul GG, Jimenez SA. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology. 1995; 63 (1) 48-56
    CrossrefPubMedGoogle Scholar
  • 23 Ingegnoli F, Boracchi P, Gualtierotti R, Lubatti C, Meani L, Zahalkova L et al. Prognostic model based on nailfold ca-pillaroscopy for identifying Raynaud’s phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (prognostic index for nailfold capillaroscopic examination). Arthritis Rheum. 2008; Jul 58 (7) 2174-82
    CrossrefPubMedGoogle Scholar
  • 24 Lunardi C, Bason C, Navone R, Millo E, Damonte G, Corrocher R et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med. 2000; Oct 6 (10) 1183-6
    CrossrefPubMedGoogle Scholar
  • 25 Zhu S, Evans S, Yan B, Povsic TJ, Tapson V, Goldschmidt-Clermont PJ et al. Transcriptional regulation of Bim by FOXO3a and Akt mediates scleroderma serum-induced apoptosis in endothelial progenitor cells. Circulation. 2008; Nov 18 118 (21) 2156-65
    CrossrefPubMedGoogle Scholar
  • 26 Del Papa N, Quirici N, Soligo D, Scavullo C, Cortiana M, Borsotti C et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum. 2006; Aug 54 (8) 2605-15
    CrossrefPubMedGoogle Scholar
  • 27 Cipriani P, Guiducci S, Miniati I, Cinelli M, Urbani S, Marrelli A et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum. 2007; Jun 56 (6) 1994-2004
    CrossrefPubMedGoogle Scholar
  • 28 Shi-wen X, Kennedy L, Renzoni EA, Bou-Gharios G, du Bois RM, Black CM et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum. 2007; Dec 56 (12) 4189-94
    CrossrefPubMedGoogle Scholar
  • 29 Warrington KJ, Nair U, Carbone LD, Kang AH, Postlethwaite AE. Characterisation of the immune response to type I collagen in scleroderma. Arthritis Res Ther. 2006; 8 (4) R136
    CrossrefPubMedGoogle Scholar
  • 30 Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA. 2003; Oct 14 100 (21) 12319-24
    CrossrefPubMedGoogle Scholar
  • 31 Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum. 2000; Nov 43 (11) 2550-62
    CrossrefPubMedGoogle Scholar
  • 32 Zhou X, Tan FK, Milewicz DM, Guo X, Bona CA, Arnett FC. Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the “scleroderma phenotype”. J Immunol. 2005; Oct 1 175 (7) 4555-60
    PubMedGoogle Scholar
  • 33 Sato S, Hayakawa I, Hasegawa M, Fujimoto M, Takehara K. Function blocking autoantibodies against matrix metallo-proteinase-1 in patients with systemic sclerosis. J Invest Dermatol. 2003; Apr 120 (4) 542-7
    CrossrefPubMedGoogle Scholar
  • 34 Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006; Jun 22 354 (25) 2667-76
    CrossrefPubMedGoogle Scholar
  • 35 Aliprantis AO, Wang J, Fathman JW, Lemaire R, Dorfman DM, Lafyatis R et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Sci USA. 2007; Feb 20 104 (8) 2827-30
    CrossrefPubMedGoogle Scholar
  • 36 Bucala R. Circulating fibrocytes: cellular basis for NSF. J Am Coll Radiol. 2008; Jan 5 (1) 36-9
    CrossrefPubMedGoogle Scholar
  • 37 Yazawa N, Kikuchi K, Ihn H, Fujimoto M, Kubo M, Tamaki T et al. Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis. J Am Acad Dermatol. 2000; Jan 42 (1) Pt 1 70-5
    CrossrefPubMedGoogle Scholar
  • 38 Kuroda K, Shinkai H. Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res. 1997; Sep 289 (10) 567-72
    CrossrefPubMedGoogle Scholar
  • 39 Xu S, Denton CP, Holmes A, Dashwood MR, Abraham DJ, Black CM. Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol. 1998; 31 Suppl 1 S360-3
    CrossrefPubMedGoogle Scholar
  • 40 Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006; Oct 65 (10) 1336-40
    CrossrefPubMedGoogle Scholar
  • 41 Launay D, Humbert M, Hachulla E. [Pulmonary arterial hypertension and systemic sclerosis]. Presse Med. 2006; Dec 35 (12) Pt 2 1929-37
    CrossrefPubMedGoogle Scholar
  • 42 Seibold J, Benza R, Davie N, Frost A, Gaine S, Hill NS et al. Long term results of sitaxentan therapy in pulmonary arterial hypertension (PAH) asociated with connective tissue disease (CTD). European League Against Rheumatism (EU-LAR) Congress; 2009 June 10–13; Copenhagen, Denmark.
    PubMed
  • 43 Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000; Mar 21 132 (6) 425-34
    PubMedGoogle Scholar
  • 44 Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galie N et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007; Dec 34 (12) 2417-22
    PubMedGoogle Scholar
  • 45 Becker M, Brückner CS, Scherer H, Burmester GR, Riemekasten G Effect of sildenafil on digital ulcers in systemic sclerosis – analysis from a single centre study. Long term results of sitaxentan therapy in pulmonary arterial hypertension (PAH) asociated with connective tissue disease (CTD). European League Against Rheumatism (EULAR) Congress; 2009 June 10–13; Copenhagen, Denmark.
    PubMed
  • 46 Hunzelmann N, Moinzadeh P, Genth E, Krieg T, Lehmacher W, Melchers I et al. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther. 2009; Mar 4 11 (2) R30
    CrossrefPubMedGoogle Scholar
  • 47 Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006; Jun 22 354 (25) 2655-66
    CrossrefPubMedGoogle Scholar
  • 48 Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007; Nov 15 176 (10) 1026-34
    CrossrefPubMedGoogle Scholar
  • 49 Low AH, Lee P. Indirect evidence for the efficacy of methotrexate in diffuse systemic sclerosis. J Rheumatol. 2008; Nov 35 (11) 2286
    PubMedGoogle Scholar
  • 50 Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2008; Feb 133 (2) 455-60
    CrossrefPubMedGoogle Scholar
  • 51 Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008; Jan 102 (1) 150-5
    CrossrefPubMedGoogle Scholar
  • 52 Bosello S, De Santis M, Tolusso B, Zoli A, Ferraccioli G. Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. Ann Rheum Dis. 2005; Dec 20 143 (12) 918-20
    PubMedGoogle Scholar
  • 53 Koca SS, Isik A, Ozercan IH, Ustundag B, Evren B, Metin K. Effectiveness of etanercept in bleomycin-induced experimental scleroderma. Rheumatology (Oxford). 2008; Feb 47 (2) 172-5
    PubMedGoogle Scholar
  • 54 Denton CP, Engelhart M, Tvede N, Wilson H, Khan K, Shiwen X et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2009; Sep 1 68 (9) 1433-9
    CrossrefPubMedGoogle Scholar
  • 55 Ernst JA, Li H, Kim HS, Nakamura GR, Yansura DG, Vandlen RL. Isolation and characterization of the B-cell marker CD20. Biochemistry. 2005; Nov 22 44 (46) 15150-8
    CrossrefPubMedGoogle Scholar
  • 56 Smith VP, Van Praet JT, Vandooren BR, Vander BCruyssen, Naeyaert JM, Decuman S et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2008; Dec 22.
    PubMedGoogle Scholar
  • 57 Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009; Jan 29 60 (2) 578-83
    CrossrefPubMedGoogle Scholar
  • 58 Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 2007; Jan 56 (1) 323-32
    CrossrefPubMedGoogle Scholar
  • 59 Wang S, Wilkes MC, Leof EB, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-pathway and reduces renal fibrogenesis in vivo . FASEB J. 2005; 19: 1-11
    CrossrefPubMedGoogle Scholar
  • 60 Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 2009; Jan 60 (1) 219-24
    CrossrefPubMedGoogle Scholar
  • 61 Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-_ and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004; 114: 1308-16
    CrossrefPubMedGoogle Scholar
  • 62 Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 2007; Jan 56 (1) 311-22
    CrossrefPubMedGoogle Scholar
  • 63 Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 2008; 60: 219-24
    PubMedGoogle Scholar
  • 64 Sabnani I, Zucker MJ, Rosenstein ED, Baran DA, Arroyo LH, Tsang P et al. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology. 2009; 48 (1) 49-52
    CrossrefPubMedGoogle Scholar
  • 65 Spiera RF, Gordon JK, Mehta M, Kirou KA, Lyman S, Kloiber SA et al. Abstract 1222: Phase IIa Trial of Imatinib Mesylate (Gleevec) in the Treatment of Diffuse Systemic Sclerosis – An Interim Analysis. American College of Rheumatology (ACR) Annual Scientific Meeting; 2008 Oct 24–29; San Francisco, CA, USA.
    PubMed
  • 66 Khanna D, Saggar P, Clements P, Maranian P, Indulkar L, Burger D et al. OP-0143. Open labeled study of imatinib mesulate (Gleevec) in the treatment of systemic sclerosis-associated active interstitial lung disease (SSC-ILD): Preliminary results. Long term results of sitaxentan therapy in pulmonary arterial hypertension (PAH) asociated with connective tissue disease (CTD). European League Against Rheumatism (EULAR) Congress; 2009 June 10–13; Copenhagen, Denmark.
    PubMed
  • 67 Postlethwaite AE, Wong WK, Clements P, Chatterjee S, Fessler BJ, Kang AH et al. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum. 2008; Jun 58 (6) 1810-22
    CrossrefPubMedGoogle Scholar
  • 68 Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol. 2009; Feb 174 (2) 519-33
    CrossrefPubMedGoogle Scholar
  • 69 Akhmetshina A, Dees C, Busch N, Beer J, Zimmer A, Distler O et al. FRI-0327. The cannabinoid receptor CB2 exerts antifibrotic efects in experimental dermal fibrosis. Long term results of sitaxentan therapy in pulmonary arterial hypertension (PAH) asociated with connective tissue disease (CTD). European League Against Rheumatism (EULAR) Congress; 2009 June 10–13; Copenhagen, Denmark.
    PubMed
  • 70 Hügle T, van Laar JM. Stem cell transplantation for rheumatic autoimmune diseases. Arthritis Res Ther. 2008; 10: 217
    CrossrefPubMedGoogle Scholar
  • 71 Vonk MC, Marjanovic Z, van den Hoogen FH, Zohar S, Schattenberg AV, Fibbe WE et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis. 2008; Jan 67 (1) 98-104
    CrossrefPubMedGoogle Scholar
  • 72 Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen CS, Godwin JD et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood. 2007; Aug 15 110 (4) 1388-96
    CrossrefPubMedGoogle Scholar
  • 73 Nash RA, McSweeney PA, Nelson JL, Wener M, Georges GE, Langston AA et al. Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. Arthritis Rheum. 2006; Jun 54 (6) 1982-6
    CrossrefPubMedGoogle Scholar
  • 74 Khorshid O, Hosing C, Bibawi S, Ueno N, Reveille J, Mayes MD et al. Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus. J Rheumatol. 2004; Dec 31 (12) 2513-6
    PubMedGoogle Scholar
  • 75 Loh Y, Oyama Y, Statkute L, Verda L, Quigley K, Yaung K, et al. Non-myeloablative allogeneic hematopoietic stem cell transplantation for severe systemic sclerosis: graft-versus-autoimmunity without graft-versus-host disease?. Bone Marrow Transplant. 2007; Apr 39 (7) 435-7
    CrossrefPubMedGoogle Scholar
  • 76 Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008; May 10 371 (9624) 1579-86
    CrossrefPubMedGoogle Scholar
  • 77 Fick S, Christopeit M, Schendel M Abstract 1769: Allogeneic mesenchymal stem cell transplantation in progressive systemic sclerosis. American College of Rheumatology (ACR) Annual Scientific Meeting; 2008 Oct 24–29; San Francisco, CA, USA.
    PubMed